Skip to Content

Matthew H.G. Katz, M.D., F.A.C.S.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1999 New York Medical College, New York, NY, MD, Alpha Omega Alpha, Doctor of Medicine
1994 University of California, Berkeley, CA, BA, Economics

Postgraduate Training

8/2006-7/2008 Clinical Fellowship, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Steven Curley, MD
8/2002-7/2006 Postdoctoral Researcher, Moores Comprehensive Cancer Center, University of California, San Diego, CA, Michael Bouvet, MD
8/2000-7/2006 Categorical Residency, General Surgery, University of California, San Diego, CA
8/1999-7/2000 Clinical Internship, General Surgery, University of California, San Diego, CA


Institutional Committee Activities

Chair, The Pancreas Cancer Multidisciplinary Conference, 2012-present
Education Co-Director, Minimally Invasive New Technology in Oncologic Surgery (MINTOS), 2012-2013
Member, Perioperative Value Analysis Team,The University of Texas MD Anderson Cancer Center, 2010-present
Member, Department of Surgical Oncology Research Education Committee, 2010-present
Member, The Pancreas Cancer Multidisciplinary Conference, 2010-present
Member, Transfusions Committee, 2010-present
Member, Minimally Invasive New Technology in Oncologic Surgery (MINTOS), 2010-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Katz MH, Lee JE, Pisters PW, Skoracki R, Tamm E, Fleming JB. Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques. J Am Coll Surg 215(2):e11-18, 8/2012.
2. Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW, Vauthey JN, Charnsangavej C, Tamm E, Crane CH, Balachandran A. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118(23). e-Pub 5/2012.
3. Katz MH, Hu CY, Fleming JB, Pisters PW, Lee JE, Chang GJ. Clinical Calculator of Conditional Survival Estimates for Resected and Unresected Survivors of Pancreatic Cancer. Arch Surg 147(6). e-Pub 2/2012. PMID: 22351874.
4. Katz MH, Wang H, Balachandran A, Bhosale P, Crane CH, Wang X, Pisters PW, Lee JE, Vauthey JN, Abdalla EK, Wolff R, Abbruzzese J, Varadhachary G, Chopin-Laly X, Charnsangavej C, Fleming JB. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg 16(1):68-78; discussion 78-9, 1/2012. e-Pub 11/2011. PMID: 22065318.
5. Katz MH, Wolff R, Crane CH, Varadhachary G, Javle M, Lin E, Evans DB, Lee JE, Fleming JB, Pisters PW. Survival and Quality of Life of Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Interferon-Based Chemoradiation: A Phase II Trial. Annals of Surgical Oncology 18(13). e-Pub 6/2011. PMID: 21701927.
6. Katz MH, Taylor TH, Al-Refaie WB, Hanna MH, Imagawa DK, Anton-Culver H, Zell JA. Adenosquamous Versus Adenocarcinoma of the Pancreas: A Population-Based Outcomes Analysis. J Gastrointest Surg 15(1). e-Pub 11/2010. PMID: 21082275.
7. Katz MH, Merchant NB, Brower S, Branda M, Posner MC, William Traverso L, Abrams RA, Picozzi VJ, Pisters PW, The American College of Surgeons Oncology Group. Standardization of Surgical and Pathologic Variables is Needed in Multicenter Trials of Adjuvant Therapy for Pancreatic Cancer: Results from the ACOSOG Z5031 Trial. Ann Surg Oncol 18(2). e-Pub 9/2010. PMID: 20811779.
8. Tran Cao HS, Bouvet M, Kaushal S, Keleman A, Romney E, Kim G, Fruehauf J, Imagawa DK, Hoffman RM, Katz MH. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol Cancer Ther 9(7):2068-78, 7/2010. e-Pub 7/2010. PMID: 20606044.
9. Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Sun CC, Wang H, Crane CH, Lee JH, Tamm EP, Abbruzzese JL, Evans DB. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 17(7):1794-801, 7/2010. e-Pub 2/2010. PMCID: PMC2889288.
10. Lambert LA, Armstrong TS, Lee JJ, Liu S, Katz MH, Eng C, Wolff RA, Tortorice ML, Tansey P, Gonzalez-Moreno S, Lambert DH, Mansfield PF. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol 16(8):2181-7, 8/2009. e-Pub 5/2009. PMCID: PMC2711905.
11. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16(4):836-47, 4/2009. e-Pub 2/2009. PMID: 19194760.
12. Katz MH, Fleming JB, Pisters PW, Lee JE, Evans DB. Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy. Ann Surg 248(6):1098-102, 12/2008. PMID: 19092356.
13. Mortenson MM, Katz MH, Tamm EP, Bhutani MS, Wang H, Evans DB, Fleming JB. Current diagnosis and management of unusual pancreatic tumors. Am J Surg 196(1):100-13, 7/2008. e-Pub 5/2008. PMID: 18466869.
14. Katz MH, Mortenson MM, Wang H, Hwang R, Tamm EP, Staerkel G, Lee JH, Evans DB, Fleming JB. Diagnosis and management of cystic neoplasms of the pancreas: an evidence-based approach. J Am Coll Surg 207(1):106-20, 7/2008. e-Pub 4/2008. PMID: 18589369.
15. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR, Hwang RF. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206(5):833-46; discussion 846-8, 5/2008. e-Pub 3/2008. PMID: 18471707.
16. Tsuji K, Yang M, Jiang P, Maitra A, Kaushal S, Yamauchi K, Katz MH, Moossa AR, Hoffman RM, Bouvet M. Common bile duct injection as a novel method for establishing red fluorescent protein (RFP)-expressing human pancreatic cancer in nude mice. JOP 7(2):193-9, 2006. e-Pub 3/2006. PMID: 16525203.
17. Bouvet M, Spernyak J, Katz MH, Mazurchuk RV, Takimoto S, Bernacki R, Rustum YM, Moossa AR, Hoffman RM. High correlation of whole-body red fluorescent protein imaging and magnetic resonance imaging on an orthotopic model of pancreatic cancer. Cancer Res 65(21):9829-33, 11/2005. PMID: 16267005.
18. Katz MH, Savides TJ, Moossa AR, Bouvet M. An evidence-based approach to the diagnosis and staging of pancreatic cancer. Pancreatology 5(6):576-90, 2005. e-Pub 8/2005. PMID: 16110256.
19. Katz MH, Bouvet M, Al-Refaie W, Gilpin EA, Moossa AR. Non-pancreatic periampullary adenocarcinomas: an explanation for favorable prognosis. Hepatogastroenterology 51(57):842-6, May-Jun, 5/2004. PMID: 15143931.
20. Alrefaie W, Katz MH, Easter DW, Yi ES, Weidner N, Savides TJ, Moossa AR, Bouvet M. Simultaneous serous cystadenoma of the pancreas and mucinous cystadenoma of the appendix. JOP 5(2):97-100, 3/2004. PMID: 15007191.
21. Katz MH, Bouvet M, Takimoto S, Spivack D, Moossa AR, Hoffman RM. Survival efficacy of adjuvant cytosine-analogue CS-682 in a fluorescent orthotopic model of human pancreatic cancer. Cancer Res 64(5):1828-33, 3/2004. PMID: 14996746.
22. Katz MH, Takimoto S, Spivack D, Moossa AR, Hoffman RM, Bouvet M. An imageable highly metastatic orthotopic red fluorescent protein model of pancreatic cancer. Clin Exp Metastasis 21(1):7-12, 2004. PMID: 15065597.
23. Katz MH, Bouvet M, Takimoto S, Spivack D, Moossa AR, Hoffman RM. Selective antimetastatic activity of cytosine analog CS-682 in a red fluorescent protein orthotopic model of pancreatic cancer. Cancer Res 63(17):5521-5, 9/2003. PMID: 14500389.
24. Katz MH, Spivack DE, Takimoto S, Fang B, Burton DW, Moossa AR, Hoffman RM, Bouvet M. Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter. Ann Surg Oncol 10(7):762-72, 8/2003. PMID: 12900367.
25. Katz MH, Takimoto S, Spivack D, Moossa AR, Hoffman RM, Bouvet M. A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. J Surg Res 113(1):151-60, 7/2003. PMID: 12943825.
26. Katz MH, Barone RM. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am 12(3):673-88, 7/2003. PMID: 14567024.
27. Du E, Katz MH, Weidner N, Yoder S, Moossa AR, Shabaik A. Ampullary pancreatoblastoma in an elderly patient: a case report and review of the literature. Archives of Pathology and Laboratory Medicine, 127(11):1501-1505, 2003.
28. Zhou W, Katz MH, Deftos L, Snyder C, Baird S, Bouvet M. Metachronous double parathyroid adenomas involving two different cell types: chief and oxyphil cell: a case report. Endocrine Practice, 9(6):522-525, 2003.
29. Katz MH, Bouvet M. Novel gene therapy approaches to pancreatic cancer. Int J Gastrointest Cancer 33(1):89-97, 2003. PMID: 12909741.

Invited Articles

1. Katz MH, Fleming JB, Lee JE, Pisters PW. Current status of adjuvant therapy for pancreatic cancer. Oncologist 15(11):1205-13, 2010. e-Pub 11/2010. PMID: 21045189.
2. Katz MH, Choi EA, Pollock RE. Current concepts in multimodality therapy for retroperitoneal sarcoma. Expert Rev Anticancer Ther 7(2):159-68, 2/2007. PMID: 17288527.


1. Katz MH, Pisters PW, Lee JE, Fleming JB. Borderline resectable pancreatic cancer: what have we learned and where do we go from here? Annals of Surgical Oncology 18(3):608-10, 3/2011. PMID: 21136179.

Last updated: 6/20/2016